Drug Profile


Latest Information Update: 01 May 2002

Price : $50

At a glance

  • Originator University of Oklahoma Health Sciences Center
  • Class Class Ib antiarrhythmics
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Arrhythmias

Most Recent Events

  • 26 Feb 1996 A study has been added to the pharmacodynamics section
  • 17 Oct 1995 A preclinical study has been added to the pharmacokinetic section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top